QuiaPEG

Newsroom

Filter news by year:
Page:
123456789
May 24, 2020

The shareholders of QuiaPEG Pharmaceuticals Holding AB, company reg. no 556658-0196, are hereby given notice to attend the Annual General Meeting to be held on June 22, 2020 at 2.00 pm at MAQS Advokatbyrå, Hamngatan 13 in Stockholm. Registration to the Annual General Meeting begins at 1.30 pm.

May 18, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops improved versions of clinically validated or already approved drugs, today announced it signed an agreement with the Chinese pharmaceutical company Chengdu Shengnuo Biopharm Co.,Ltd (”SNBio”), which pays $200,000 (approx. 2 MSEK) in exchange for being able to evaluate for a limited time a proprietary drug together with one of QuiaPEG's releasable activated PEGs from the technology platform Uni-Qleaver®.

May 06, 2020

The Board of Directors of QuiaPEG Pharmaceuticals Holding AB (publ) (the "Company") has decided to postpone the Annual General Meeting, which was originally planned to be held on June 11, 2020. The new date for the Annual General Meeting is June 22, 2020. The postponement is made with regard to current uncertainties as a result of the Covid-19 pandemic. The Company considers that a postponement improves the Company's ability to conduct the Annual General Meeting in a satisfactory manner. Notice of the Annual General Meeting and publication of the Company's annual report will be published in the usual way, taking into account the provisions of the Companies Act and the Articles of Association. Thus, the annual report will be published no later than June 8, 2020.

Apr 07, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today announced it has signed an agreement with the German company Celares GmbH to develop an optimized process suitable for large scale production of products based onQuiaPEG’sUni-Qleaver technology, including QPG-1029 according to current Good Manufacturing Practice (cGMP).

Page:
123456789
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message